Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17317605 | 0.94 | SMN1; SMN2 (0.45) | MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL19110808 | 0.91 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17317758 | 0.89 | ENPP2 (0.52) | TSHRNPSR1POLBENPP2 | |
| SCHEMBL17317792 | 0.88 | KCNK3 (0.42) | SMN1; SMN2TSHRGAAENPP2 | |
| SCHEMBL17317531 | 0.87 | ALDH1A1 (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17317778 | 0.85 | KCNK3 (0.44) | MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17317563 | 0.85 | ENPP2 (0.47) | ENPP2 | |
| SCHEMBL19110820 | 0.84 | SMN1; SMN2 (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17317526 | 0.84 | ENPP2 (0.50) | TSHRNPSR1ENPP2 | |
| SCHEMBL17317604 | 0.84 | KCNK3 (0.44) | TSHRNPSR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | claimed |
| US-10144732-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
| EP-3152206-A1 | ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | MEN1 1850/4885KMT2A 1485/4885SMN1; SMN2 119/4885 |
| US-10144732-B2 | ATX modulating agents | ENPP2, ATXN10, ATXN2 | MEN1 1850/4885KMT2A 1483/4885SMN1; SMN2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.